期刊
BASIC RESEARCH IN CARDIOLOGY
卷 105, 期 1, 页码 129-137出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00395-009-0056-9
关键词
Adenosine; A(2b) receptor; AMP579; Cardioprotection; Myocardial infarction
资金
- Heart, Lung, and Blood Institute of the National Institutes of Health [HL-20468]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020648] Funding Source: NIH RePORTER
The mixed A(1)/A(2a)-adenosine agonist AMP579 given at reperfusion is protective in animal models of myocardial infarction. Receptor-blocking studies have indicated that the protection came from an adenosine receptor (AR), but neither A(1)- nor A(2a)-selective agonists could duplicate its protection. We recently found that A(2b)-selective agonists given at reperfusion are protective, and, therefore, tested whether AMP579 might also be an A(2b) agonist. We used human embryonic kidney cells overexpressing human A(2b) receptors as an assay system. In these cells, A(2b) receptor occupancy causes phosphorylation of ERK. AMP579 induced ERK phosphorylation with an EC50 of 250 nM and this phosphorylation could be blocked by MRS1754 or PSB1115, two highly selective blockers of human A(2b) receptors. We attempted to confirm our A(2b) hypothesis in a rabbit heart model of ischemia-reperfusion. AMP579 (500 nM) for 1 h starting at reperfusion reduced infarct size in isolated rabbit hearts exposed to 30 min of regional ischemia and 2 h of reperfusion (12.9 +/- A 2.2% infarction of risk zone vs. 32.0 +/- A 1.9% in untreated hearts). PSB1115 (500 nM) given for the first 15 min of reperfusion blocked AMP579's protection (32.2 +/- A 3.1% infarction) which is consistent with an A(2b) mechanism. We conclude that AMP579 is a non-selective, but potent A(2b)-AR agonist, and that its protection against infarction is through that receptor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据